All In Biotech

Drug Trial Radar · NCT00642980

Prevention of Very Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis

Randomized Multicenter Trial for the Prevention of Preterm Delivery by Testing for and Treatment of Bacterial Vaginosis in the First Trimester of Pregnancy

Last checked: Nov 19, 2026Latest source record: Oct 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,105 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,105

Actual

Start

Apr 2006

Primary completion

Jun 2011

Study completion Jun 2011

Sponsor

Lead sponsor
University Hospital, LilleAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
Mar 25, 2008

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Background. Anomalies of the vaginal flora (bacterial vaginosis, BV) are associated with an increased risk of late abortions and preterm birth. Studies of antibiotic treatment of BV to reduce the risk of prematurity have not found a statistically significant diminution of risk (\<= 32 wks: OR=0.49 \[0.05-5.1\], \< 37 wks: OR=0.83 \[0.59-1.17\]).A partial explanation of these findings is that some of these treatment were administered vaginally, most often during the second or third trimester Aim: To reduce the frequency of late abortions and very preterm birth by prescribing clindamycin vs placebo to patients diagnosed with BV before 13 weeks.

Conditions

  • Pregnancy

Interventions

  • ClindamycinDrug

    300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart

  • PlaceboDrug

    Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart

  • ClindamycinDrug

    300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Premature delivery (16 to 32 weeks of gestation)Time frame: At delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hopital Jeanne de Flandre

    Lille, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.